Cerepeut Logo

Inhibiting mitochondrial reverse electron transport that drives neurodegeneration

Small molecule therapeutic approach to treat PSP and Parkinson’s



Team
Hua Tu, PhD
Hua Tu, PhD
President and CEO
  • 20+ years of drug development experience
  • Previously, founder and CEO of LakePharma
Dave Galgoczy, PhD
Dave Galgoczy, PhD
Head of Business Development
  • 15+ years of closing biotech partnerships
  • Experience across CDMO, biomanufacturing, and drug development services
  • PhD in Genetics, UCSF
Jim Liu, PhD
Jim Liu, PhD
Head of Chemistry
  • 25+ years of small molecule drug R&D
  • Previously Teon, Amgen
Abby Kochavi
Abby Kochavi
Chief of Staff
  • 25+ years of biotech operations experience
  • Previously LakePharma, Curia
Bingwei Lu, PhD
Bingwei Lu, PhD
Co-Founder and Scientific Advisor
  • Professor of Pathology, Stanford University
  • Member, Stanford Cancer Institute
  • Member, Wu Tsai Neurosciences Institute
  • Member, Glenn Center for Biology of Aging Research at Stanford
Su Guo, PhD
Su Guo, PhD
Co-Founder and Scientific Advisor
  • Professor of Bioengineering, UCSF
  • Member, Kavli Institute of Fundamental Neuroscience
  • Member, Institute of Human Genetics
  • Member, Bakar Aging Research Institute

Executive Summary

Cerepeut in Brief

Focus
Neurodegeneration driven by reverse electron transport. Lead indications progressive supranuclear palsy (PSP) and Parkinson’s disease; Alzheimer’s disease in parallel
Product
CP-235, an oral, brain-penetrant small molecule
Mechanism
Novel: inhibits excess reverse electron transport (RET) at Complex I
Evidence
CP-235 efficacy across fly, mouse and human iPSC tauopathy models (Neuron, 2026) and in the MPTP Parkinson’s mouse model (Mol Neurodegener Adv, 2026). Separately, elevated RET is observed in human PSP and AD patient brain tissue (Neuron, 2026)
Stage
IND-enabling studies; IND submission targeted Q4 2027

The Mechanism

The RETau Loop: Self-Perpetuating, and CP-235 Breaks It

Phosphorylated tau enters mitochondria and drives reverse electron transport at Complex I. RET in turn drives more tau phosphorylation, so every turn of the loop makes more p-tau.

The RETau loop: p-tau builds up, enters mitochondria and binds Complex I at NDUFS3, driving reverse electron transport (RET), which raises ROS and lowers NAD+/NADH, switching on tau kinases that make more p-tau. CP-235 reduces p-tau binding at NDUFS3, stopping the loop.
Peer-Reviewed · Neuron, October 2026

“Tau-induced mitochondrial reverse electron transport drives neurodegeneration”

Li, Rimal, Bhurtel, Yeung, B.G. Lu, Grinberg, Spina, Cobos Sillero, Seeley, Guo & Lu · Stanford University and UCSF · Read the full study

1
A new function of tau
p-tau enters mitochondria and binds the Complex I subunit NDUFS3 to promote reverse electron transport
2
The RETau loop
Elevated RET in turn drives more tau hyperphosphorylation: a self-perpetuating loop, and a new, targetable mechanism
3
Validated in models and patients
RET inhibition is protective across fly, mouse and human iPSC models; the same RET signature appears in human PSP and AD brain tissue
4
CP-235 breaks the loop
Oral CP-235 inhibits tau-driven RET and spares forward electron transport

Oral CP-235 in tauopathy mice

  • Memory rescued: spatial memory in the Morris water maze; dose-dependent rescue (25–100 mg/kg) in fear conditioning, open-field and elevated-plus-maze tests
  • Brain atrophy reduced: cortical thickness and brain volume preserved on MRI
  • Neurons protected: NeuN-positive neurons preserved vs. vehicle
  • Neuroinflammation reduced: astrocyte and microglial activation and CD8⁺ T-cell infiltration lowered
  • p-tau lowered

RET is activated in PSP and Alzheimer’s patient brain

  • ROS increased, NAD⁺/NADH decreased in PSP (pons) and Alzheimer’s (cortex) patient brain cells
  • RET elevated, forward electron transport not significantly changed in mitochondria purified from the same tissue
  • Enhanced p-tau–NDUFS3 interaction in PSP and Alzheimer’s brain
  • Three of the loop’s four steps are already seen in patient tissue
Not a Complex I inhibitor. CP-235 inhibits the disease-driven excess of reverse electron transport while sparing forward electron transport, the ATP-generating direction.

Source: Li et al., Neuron 2026. Mice dosed orally for 2–4 months (rTg4510 tauopathy model). Patient tissue from the UCSF Memory & Aging Center and Stanford brain bank. The paper’s “CPT” is CP-235.


Disease Indication

PSP and Tauopathy

Progressive supranuclear palsy: the fastest, cleanest clinical read on the mechanism

No approved therapy
Disease-modifying options do not exist, leaving a clear regulatory and commercial lane.
Orphan, fast-progressing
~30,000 US patients, rapid decline, enabling smaller, shorter, cheaper trials.
Validated endpoint
The PSP Rating Scale (PSPRS) is an accepted primary endpoint.
Best mechanistic match
PSP is a pure 4R tauopathy; 4R tau drives more RET than 3R, making it the most direct in-human test of the mechanism.
Beyond PSP. Normal tau (both isoforms) drives RET once phosphorylated, and the RET signature is present in Alzheimer’s patient tissue. Alzheimer’s disease runs in parallel, complementary to anti-amyloid antibodies.

~30,000 US: CurePSP (likely an underestimate given frequent misdiagnosis). Li et al., Neuron 2026.


Disease Indication

Parkinson’s Disease

Two established drivers of Parkinson’s converge on reverse electron transport, and oral CP-235 acts on both

Mitochondrial dysfunction

Complex I deficiency in the Parkinson’s substantia nigra is well documented, and MPTP and rotenone, the toxins that model the disease, both inhibit Complex I.

α-Synuclein

SNCA mutations cause Parkinson’s, and phosphorylated α-synuclein is the hallmark of Lewy pathology. A Complex I insult alone is enough to raise it: phosphorylated α-synuclein rises in the MPTP model.

One process to inhibit. Reverse electron transport consumes NAD⁺ and makes superoxide. Both drivers run through it, and oral CP-235 inhibits it.

Oral CP-235 in the MPTP Parkinson’s mouse model, published 2026

  • RET corrected, dose-dependently: in mitochondria purified from substantia nigra and striatum, at every dose tested
  • Forward electron transport and Complex I activity restored
  • Motor function rescued: beam walking, challenging beam, cylinder rearings and rotarod all recover with dose
  • Dopaminergic neurons and striatal terminals preserved
  • Phosphorylated α-synuclein reduced
  • Effective when dosing began after the toxin

Source: Bhurtel, Rimal, Li & Lu, Molecular Neurodegeneration Advances 2026. The paper’s “CPT” is CP-235.